Personalized immunotherapy prediction for melanoma and other cancers
Part of Cancer, Infections, Skin clinical trials.
This trial is testing a new way to predict which immunotherapy might work best for your cancer. It uses a sample of your tumor to look for personal markers, so your treatment can be tailored to you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have melanoma or another type of cancer that can be treated with immunotherapy.
- You must have a tumor tissue sample available (from a past surgery or a planned new biopsy).
- Your cancer is either early stage but high risk, or has spread to lymph nodes or other parts of the body (stage II, III, or IV).
- You have not had active hepatitis B, hepatitis C, or HIV/AIDS.
- Your doctor expects you to live at least six more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes). The cells are taken from a tumor sample, multiplied in a lab, and given back to you to help fight the cancer. It's for people with melanoma that has not responded to standard immunotherapy.
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests a combination of immunotherapy treatments for advanced melanoma that has not responded to standard therapy. The goal is to use your own immune cells to fight the cancer more effectively.
This study looks at immune cells in your blood to find patterns that might show how well a treatment called anti-PD1 immunotherapy works for melanoma. Your participation could help doctors better understand who benefits from this therapy.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.